Oral cancer drug study
Oral squamous cell carcinoma
Cornell is studying trametinib, an oral medication, to understand why some canine oral squamous cell carcinomas respond while others do not.
Where research is focused
- Eligibility: Dogs evaluated at Cornell University Hospital for Animals with a confirmed oral squamous cell carcinoma.
- Study support: Study visits, procedures, and medication are covered; dogs that complete the study may receive an additional care credit.
- Where: Cornell University · Ithaca, New York
Full study title
A new drug for oral squamous cell carcinoma in dogs